A phase III, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of antegren (Natalizumab) in maintaining clinical response and remission in Crohn’s disease (ENACT-2)
Titel:
A phase III, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of antegren (Natalizumab) in maintaining clinical response and remission in Crohn’s disease (ENACT-2)
Auteur:
Sandborn, W. Colombel, J.-F. Enns, R. Feagan, B. Hanauer, S. Lawrance, I. Panaccione, R. Sanders, M. Schreiber, S. Targan, S. van Deventer, S. Rutgeerts, P.